Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Patton

Surgery Osage Beach, MO Doctor of Osteopathy

NPI 1194737346 CMS profile 190470

54 Hospital Dr, Ste 205, Osage Beach, MO 65065

Open in the dashboard

General payments

$7,281

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Patton of Osage Beach, MO is reported in the CMS Open Payments database as having received $7,281 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $162 8
2024 General $255 10
2023 General $4,624 17
2022 General $276 10
2021 General $503 8
2020 General $288 13
2019 General $1,173 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Patton
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to John Patton were reported at $162. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year John Patton Surgery median Middle half National median
2019 $1,173 $253 $82–$1,521 $163
2020 $288 $131 $40–$706 $114
2021 $503 $168 $50–$904 $132
2022 $276 $224 $76–$1,218 $149
2023 $4,624 $253 $82–$1,255 $160
2024 $255 $279 $90–$1,381 $164
2025 $162 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,463 24 payments
  2. Stryker Corporation $440 4 payments
  3. Smith+Nephew, Inc. $170 10 payments
  4. Vertex Pharmaceuticals Incorporated $132 5 payments
  5. Ethicon US, LLC $115 6 payments
  6. Medtronic, Inc. $93 3 payments
  7. Paratek Pharmaceuticals, Inc. $92 5 payments
  8. W. L. Gore & Associates, Inc. $82 3 payments
  9. Melinta Therapeutics, Inc. $82 6 payments
  10. CONMED Corporation $58 2 payments
  11. Other $554 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $4,000 2 payments
  2. Food and Beverage $2,717 89 payments
  3. Travel and Lodging $552 3 payments
  4. Consulting Fee $11 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $4,000 2 payments
  2. Da Vinci Surgical System $1,463 22 payments
  3. SPY-PHI SYSTEM $422 3 payments
  4. COLLAGENASE SANTYL $170 10 payments
  5. NUZYRA $92 5 payments
  6. JOURNAVX $80 3 payments
  7. Signia $58 2 payments
  8. AirSeal $58 2 payments
  9. OviTex 2S $55 1 payment
  10. Mozart $53 1 payment
  11. Other $918 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

443

Median for General Surgery: 59

Drug cost

$7,984

Median for General Surgery: $393

Branded share of claims

46.7%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 26 $4,157
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 23 $1,546
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 124 $940
Pantoprazole Sodium Generic 41 $422
Cephalexin Generic 75 $202
Ibuprofen Generic 37 $153
Ondansetron Odt Ondansetron Brand 18 $134
Clindamycin Hcl Generic 13 $109
Oxycodone Hcl Generic 15 $95
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 16 $89

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$93,811

Medicare's payments for the services billed

Medicare patients

270

Average age 72

Services billed

601

146 women, 124 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 46%
Depression 29%
COPD 27%
Diabetes 24%
Ischemic heart disease 24%
Cancer 24%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record